The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications
Open accessAbstract
Type 2 diabetes mellitus (T2DM), a prevalent chronic disease affecting over 400 million people globally, is driven by genetic and environmental factors. The pathogenesis involves insulin resistance and β-cell dysfunction, mediated by mechanisms such as the dedifferentiation of β-cells, mitochondrial dysfunction, and oxidative stress. Treatment should be based on non-pharmacological therapy. Strategies such as increased physical activity, dietary modifications, cognitive-behavioral therapy are important in maintaining normal glycemia. Advanced therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, complement these treatments and offer solid glycemic control, weight control, and reduced cardiovascular risk. Complications of T2DM, such as diabetic kidney disease, retinopathy, and neuropathy, underscore the need for early diagnosis and comprehensive management to improve patient outcomes and quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Jiang, F., Zhang, Y., Cheng, S., Yang, X., Bai, M., & Zhang, M. (2023) · International Wound Journal · doi:10.1111/iwj.14530 · Cited by 7
RetractedCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 1×
“Additionally, an increased incidence of lower limb amputations has been reported in patients treated with canagliflozin [95].”
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
Nogueira, R. G., Jadhav, A. P., Haussen, D. C., Bonafe, A., Budzik, R. F., Bhuva, P., Yavagal, D. R., Ribo, M., Cognard, C., Hanel, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706442 · Cited by 5,629
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063 · cited 1×
“The appearance of one or more of these risk factors, however, may result in a worse quality of life for people with diabetes than for people without it [173].”
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Flaxman, S. R., Bourne, R. R. A., Resnikoff, S., Ackland, P., Braithwaite, T., Cicinelli, M. V., Das, A., Jonas, J. B., Keeffe, J., Kempen, J. H., et al. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30393-5 · Cited by 3,477
Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360 · cited 3×
“Therefore, the immoderate production of these hormones may promote IR [53,54].”
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Type 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural Circuits
De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchampt, A., Bäckhed, F., & Mithieux, G. (2014) · Cell · doi:10.1016/j.cell.2013.12.016 · Cited by 2,200
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Insulin and insulin resistance.
Wilcox, G. (2005) · PubMed Central · Cited by 2,028
Campbell, B. C. V., De Silva, D. A., Macleod, M. R., Coutts, S. B., Schwamm, L. H., Davis, S. M., & Donnan, G. A. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0118-8 · Cited by 1,750
Role of gut microbiota in type 2 diabetes pathophysiology
Gurung, M., Li, Z., You, H., Rodrigues, R., Jump, D. B., Morgun, A., & Shulzhenko, N. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.051 · Cited by 1,708
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Insulin and insulin resistance:
Sowers, J. R., & Frohlich, E. D. (2004) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00128-7 · Cited by 1,518
Dyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482
Branched-chain amino acids in metabolic signalling and insulin resistance
Lynch, C. J., & Adams, S. H. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.171 · Cited by 1,461
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373 · cited 1×
“SGLT2is are advised as a component of holistic treatment plans, as they not only help lower blood sugar levels but have also been shown in numerous studies to decrease the risk of chronic kidney disease (CKD) progression and cardiovascular disease (CVD) complications [94–96].”
The diagnosis of ischaemic heart pain and intermittent claudication in field surveys.
Rose, G. A. (1962) · Europe PMC (PubMed Central) · Cited by 1,320
Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010) · Population Health Metrics · doi:10.1186/1478-7954-8-29 · Cited by 1,309
Insulin action and resistance in obesity and type 2 diabetes
Czech, M. P. (2017) · Nature Medicine · doi:10.1038/nm.4350 · Cited by 1,258
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Diabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211
The integrative biology of type 2 diabetes
Roden, M., & Shulman, G. I. (2019) · Nature · doi:10.1038/s41586-019-1797-8 · Cited by 1,167
Medical treatment of peripheral arterial disease and claudication
Hiatt, W. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442108 · Cited by 1,121
Glucolipotoxicity: fuel excess and β-cell dysfunction
Poitout, V., & Robertson, R. P. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0023 · Cited by 1,092
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000471 · Cited by 1,020
Zhou, B., Rayner, A. W., Gregg, E. W., Sheffer, K. E., Carrillo-Larco, R. M., Bennett, J. E., Shaw, J. E., Paciorek, C. J., Singleton, R. K., Barradas Pires, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02317-1 · Cited by 1,013
Yang, Y., Weng, W., Peng, J., Hong, L., Yang, L., Toiyama, Y., Gao, R., Liu, M., Yin, M., Pan, C., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.018 · Cited by 1,008
Beta Cell Dysfunction and Insulin Resistance
Cerf, M. E. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00037 · Cited by 964 · cited 1×
“…results in the inability to maintain physiological glucose levels, while IR promotes the production of glucose in the liver and decreases glucose uptake in muscle, liver, and adipose tissue, thus creating a flawed feedback loop between insulin action and secretion, leading to hyperglycemia [10,11].”
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
Feldman, E. L., Nave, K.-A., Jensen, T. S., & Bennett, D. L. H. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.005 · Cited by 915
Molecular mechanisms of diabetic kidney disease
Reidy, K., Kang, H. M., Hostetter, T., & Susztak, K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72271 · Cited by 909
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“Its affinity for the GIP receptor is equivalent to that of endogenous GIP, while its affinity for the GLP-1 receptor is five times lower than that of endogenous GLP-1 [117,118].”
Type 2 diabetes in adolescents and young adults
Lascar, N., Brown, J., Pattison, H., Barnett, A. H., Bailey, C. J., & Bellary, S. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30186-9 · Cited by 824 · cited 1×
“T2DM is a complex, multisystemic metabolic disorder characterized by high blood glucose levels resulting from a progressive defect in insulin secretion or tissue resistance to insulin [4,5].”
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“Blocking DPP-4 significantly impacts incretin hormone activity by raising the levels of endogenous active peptides in the bloodstream [108].”
A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients
Hall, A. B., Yassour, M., Sauk, J., Garner, A., Jiang, X., Arthur, T., Lagoudas, G. K., Vatanen, T., Fornelos, N., Wilson, R., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0490-5 · Cited by 777
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
Perumpail, B. J., Khan, M. A., Yoo, E. R., Cholankeril, G., Kim, D., & Ahmed, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i47.8263 · Cited by 735
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Skeletal muscle inflammation and insulin resistance in obesity
Wu, H., & Ballantyne, C. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88880 · Cited by 695 · cited 2×
“…also play a role in glucose intake; in obesity, increased immune cell infiltration and the secretion of proinflammatory molecules can result in skeletal muscle inflammation, thus leading to myocyte inflammation, impaired myocyte metabolism, and the promotion of IR via paracrine effects [59].”
Pathogenesis of insulin resistance in skeletal muscle
Abdul-Ghani, M. A., & DeFronzo, R. A. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/476279 · Cited by 670
Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications
Rovira-Llopis, S., Bañuls, C., Diaz-Morales, N., Hernandez-Mijares, A., Rocha, M., & Victor, V. M. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.013 · Cited by 657
Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30141-4 · Cited by 637
Endoplasmic Reticulum Stress and Type 2 Diabetes
Back, S. H., & Kaufman, R. J. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-072909-095555 · Cited by 619
Epidemiology of Peripheral Artery Disease and Polyvascular Disease
Aday, A. W., & Matsushita, K. (2021) · Circulation Research · doi:10.1161/circresaha.121.318535 · Cited by 599
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans
Stefan, N., Schick, F., & Häring, H.-U. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.008 · Cited by 575 · cited 5×
“Normal-weight patients with a lipodystrophy-like phenotype are also strongly characterized by insulin resistance and impaired secretion of insulin [84].”
InfluentialEvidence of β-Cell Dedifferentiation in Human Type 2 Diabetes
Cinti, F., Bouchi, R., Kim-Muller, J. Y., Ohmura, Y., Sandoval, P. R., Masini, M., Marselli, L., Suleiman, M., Ratner, L. E., Marchetti, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2860 · Cited by 550
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 1×
“Its affinity for the GIP receptor is equivalent to that of endogenous GIP, while its affinity for the GLP-1 receptor is five times lower than that of endogenous GLP-1 [117,118].”
Causes, consequences, and treatment of metabolically unhealthy fat distribution
Stefan, N. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30110-8 · Cited by 541
Gæde, P., Oellgaard, J., Carstensen, B., Rossing, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2016) · Diabetologia · doi:10.1007/s00125-016-4065-6 · Cited by 528
Inactivation of specific β cell transcription factors in type 2 diabetes
Guo, S., Dai, C., Guo, M., Taylor, B., Harmon, J. S., Sander, M., Robertson, R. P., Powers, A. C., & Stein, R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65390 · Cited by 520
Diabetic retinopathy: Looking forward to 2030
Tan, T.-E., & Wong, T. Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1077669 · Cited by 511
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502
Zaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D., Khunti, K., & Davies, M. J. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12670 · Cited by 489
MafA Is a Key Regulator of Glucose-Stimulated Insulin Secretion
Zhang, C., Moriguchi, T., Kajihara, M., Esaki, R., Harada, A., Shimohata, H., Oishi, H., Hamada, M., Morito, N., Hasegawa, K., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.12.4969-4976.2005 · Cited by 488
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
Säemann, M. D., Böhmig, G. A., Österreicher, C. H., Burtscher, H., Parolini, O., Diakos, C., Stöckl, J., Hörl, W. H., & Zlabinger, G. J. (2000) · The FASEB Journal · doi:10.1096/fj.00-0359fje · Cited by 482
Hepatic insulin resistance, metabolic syndrome and cardiovascular disease
Meshkani, R., & Adeli, K. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.05.018 · Cited by 458
Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy
Lin, K., Hsih, W., Lin, Y., Wen, C., & Chang, T. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13480 · Cited by 446 · cited 1×
“DR is more common in women, but its course is worse in men [155].”
Butyrate and other short-chain fatty acids as modulators of immunity: What relevance for health?
Meijer, K., de Vos, P., & Priebe, M. G. (2010) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32833eebe5 · Cited by 443
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443
Röhrborn, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00386 · Cited by 440
Unraveling the Regulation of Hepatic Metabolism by Insulin
Titchenell, P. M., Lazar, M. A., & Birnbaum, M. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.03.003 · Cited by 437
Post Stroke Pain: Identification, Assessment, and Therapy
Harrison, R. A., & Field, T. S. (2015) · Cerebrovascular Diseases · doi:10.1159/000375397 · Cited by 419
Pdx1 Maintains β Cell Identity and Function by Repressing an α Cell Program
Gao, T., McKenna, B., Li, C., Reichert, M., Nguyen, J., Singh, T., Yang, C., Pannikar, A., Doliba, N., Zhang, T., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.002 · Cited by 413
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
High Risk of Cardiovascular Disease in Patients With Type 1 Diabetes in the U.K.
Soedamah-Muthu, S. S., Fuller, J. H., Mulnier, H. E., Raleigh, V. S., Lawrenson, R. A., & Colhoun, H. M. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1433 · Cited by 395
Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus
Petersen, K. F., & Shulman, G. I. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02554-7 · Cited by 392
Stefan, N., Yki-Järvinen, H., & Neuschwander-Tetri, B. A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 392
Potential of Surgery for Curing Type 2 Diabetes Mellitus
Rubino, F., & Gagner, M. (2002) · Annals of Surgery · doi:10.1097/00000658-200211000-00003 · Cited by 374
Mitochondrial reactive oxygen species are obligatory signals for glucose-induced insulin secretion
Leloup, C., Tourrel-Cuzin, C., Magnan, C., Karaca, M., Castel, J., Carneiro, L., Colombani, A.-L., Ktorza, A., Casteilla, L., & Pénicaud, L. (2009) · Diabetes · doi:10.2337/db07-1056 · Cited by 361 · cited 1×
“ROS in small amounts exert a beneficial effect of stimulating insulin expression and are necessary for glucose-induced insulin secretion [39].”
Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences
Leclercq, I. A., Da Silva Morais, A., Schroyen, B., Van Hul, N., & Geerts, A. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.002 · Cited by 359
Diagnosis and management of acute ischemic stroke: speed is critical
Musuka, T. D., Wilton, S. B., Traboulsi, M., & Hill, M. D. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.140355 · Cited by 358
Diabetic Neuropathy: Mechanisms, Emerging Treatments, and Subtypes
Albers, J. W., & Pop-Busui, R. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0473-5 · Cited by 357
Puddu, A., Sanguineti, R., Montecucco, F., & Viviani, G. L. (2014) · Mediators of Inflammation · doi:10.1155/2014/162021 · Cited by 342
Guo, W., Song, Y., Sun, Y., Du, H., Cai, Y., You, Q., Fu, H., & Shao, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1071465 · Cited by 335
β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition
Jurgens, C. A., Toukatly, M. N., Fligner, C. L., Udayasankar, J., Subramanian, S. L., Zraika, S., Aston-Mourney, K., Carr, D. B., Westermark, P., Westermark, G. T., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.02.036 · Cited by 329 · cited 1×
“Moreover, the increased accumulation of islet amyloid polypeptide in β -cells is also suggested as a factor leading to ER stress and the development of T2DM [48].”
Karlsson, T., Rask-Andersen, M., Pan, G., Höglund, J., Wadelius, C., Ek, W. E., & Johansson, Å. (2019) · Nature Medicine · doi:10.1038/s41591-019-0563-7 · Cited by 318
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Diabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans-Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Susztak, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 292
Min, T., & Bain, S. C. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 285
Bensellam, M., Laybutt, D. R., & Jonas, J.-C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.003 · Cited by 284
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Lee, A.-H., Heidtman, K., Hotamisligil, G. S., & Glimcher, L. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105564108 · Cited by 277
Jensen, T. S., Karlsson, P., Gylfadottir, S. S., Andersen, S. T., Bennett, D. L., Tankisi, H., Finnerup, N. B., Terkelsen, A. J., Khan, K., Themistocleous, A. C., et al. (2021) · Brain · doi:10.1093/brain/awab079 · Cited by 265
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
Li, D., Wang, T., Shen, S., Fang, Z., Dong, Y., & Tang, H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12825 · Cited by 253
Diabetes and Stroke: What Are the Connections?
Mosenzon, O., Cheng, A. Y., Rabinstein, A. A., & Sacco, S. (2023) · Journal of Stroke · doi:10.5853/jos.2022.02306 · Cited by 249
Mechanisms of insulin resistance related to white, beige, and brown adipocytes
Czech, M. P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.12.014 · Cited by 245
Anti-Obesity Effect of Lactobacillus gasseri BNR17 in High-Sucrose Diet-Induced Obese Mice
Kang, J.-H., Yun, S.-I., Park, M.-H., Park, J.-H., Jeong, S.-Y., & Park, H.-O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054617 · Cited by 230
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1425 · Cited by 222
Effect of pre-diabetes on future risk of stroke: meta-analysis
Lee, M., Saver, J. L., Hong, K.-S., Song, S., Chang, K.-H., & Ovbiagele, B. (2012) · BMJ · doi:10.1136/bmj.e3564 · Cited by 216
Liu, C. Y., & Kaufman, R. J. (2003) · Journal of Cell Science · doi:10.1242/jcs.00408 · Cited by 205
Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
Romeo, S., Sanyal, A., & Valenti, L. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.002 · Cited by 202
Early onset type 2 diabetes mellitus: an update
Strati, M., Moustaki, M., Ψαλτοπούλου, Θ., Vryonidou, A., & Paschou, S. Α. (2024) · Endocrine · doi:10.1007/s12020-024-03772-w · Cited by 201
Insulin Regulates Glucagon-Like Peptide-1 Secretion from the Enteroendocrine L Cell
Lim, G. E., Huang, G. J., Flora, N., LeRoith, D., Rhodes, C. J., & Brubaker, P. L. (2009) · Endocrinology · doi:10.1210/en.2008-0726 · Cited by 200
Cai, X., Yang, W., Gao, X., Chen, Y., Zhou, L., Zhang, S., Han, X., & Ji, L. (2018) · Obesity · doi:10.1002/oby.22066 · Cited by 181
Knapp, P., Dunn-Roberts, A., Sahib, N., Cook, L., Astin, F., Kontou, E., & Thomas, S. A. (2020) · International Journal of Stroke · doi:10.1177/1747493019896958 · Cited by 180 · cited 1×
“It has been discovered that at least one-fourth of patients after a stroke will experience one or more of these symptoms [183–185].”
Bridges between mitochondrial oxidative stress, ER stress and mTOR signaling in pancreatic β cells
Wang, J., Yang, X., & Zhang, J. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.05.007 · Cited by 180
Marinou, K., Hodson, L., Vasan, S. K., Fielding, B. A., Banerjee, R., Brismar, K., Koutsilieris, M., Clark, A., Neville, M. J., & Karpe, F. (2014) · Diabetes Care · doi:10.2337/dc13-1353 · Cited by 176
Effects of probiotics on type II diabetes mellitus: A meta-analysis
Tao, Y.-W., Gu, Y.-L., Mao, X.-Q., Zhang, L., & Pei, Y.-F. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02213-2 · Cited by 173
Loss of β-Cell Identity Occurs in Type 2 Diabetes and Is Associated With Islet Amyloid Deposits
Spijker, H. S., Song, H., Ellenbroek, J. H., Roefs, M. M., Engelse, M. A., Bos, E., Koster, A. J., Rabelink, T. J., Hansen, B. C., Clark, A., et al. (2015) · Diabetes · doi:10.2337/db14-1752 · Cited by 172
Understanding the role of the gut ecosystem in diabetes mellitus
Aw, W., & Fukuda, S. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12673 · Cited by 172
The many secret lives of adipocytes: implications for diabetes
Scherer, P. E. (2018) · Diabetologia · doi:10.1007/s00125-018-4777-x · Cited by 172
Identification of genes selectively disallowed in the pancreatic islet
Pullen, T. J., Khan, A. M., Barton, G., Butcher, S. A., Sun, G., & Rutter, G. A. (2010) · Islets · doi:10.4161/isl.2.2.11025 · Cited by 168
Diabetes Mellitus: A Risk Factor for Ischemic Stroke in a Large Biracial Population
Khoury, J. C., Kleindorfer, D., Alwell, K., Moomaw, C. J., Woo, D., Adeoye, O., Flaherty, M. L., Khatri, P., Ferioli, S., Broderick, J. P., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.001318 · Cited by 167
The Beta Cell in Type 2 Diabetes
Christensen, A. A., & Gannon, M. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1196-4 · Cited by 163
Wang, P., Karakose, E., Liu, H., Swartz, E., Ackeifi, C., Zlatanic, V., Wilson, J., González, B. J., Bender, A., Takane, K. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.005 · Cited by 162
Mishra, S. (2013) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2013/6518.3306 · Cited by 160
Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms?
Calcutt, N. A. (2020) · Pain · doi:10.1097/j.pain.0000000000001922 · Cited by 159
Predicting Early Mortality of Acute Ischemic Stroke: Score-Based Approach
Gattringer, T., Posekany, A., Niederkorn, K., Knoflach, M., Poltrum, B., Mutzenbach, J. S., Haring, H., Ferrari, J., Lang, W., Willeit, J., et al. (2019) · Stroke · doi:10.1161/strokeaha.118.022863 · Cited by 158
The Prevalence of Peripheral Arterial Disease in a Racially Diverse Population
Collins, T. C., Petersen, N. J., Suarez-Almazor, M., & Ashton, C. M. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.12.1469 · Cited by 157 · cited 1×
“The prevalence of classic claudication among patients with symptomatic PAD over the past decade has been reported to range from 7.5% to 33% [198].”
InfluentialDiabetic retinopathy for the non-ophthalmologist
Fung, T. H., Patel, B., Wilmot, E. G., & Amoaku, W. M. (2022) · Clinical Medicine · doi:10.7861/clinmed.2021-0792 · Cited by 151
Conversion of Mature Human β-Cells Into Glucagon-Producing α-Cells
Spijker, H. S., Ravelli, R. B. G., Mommaas, A. M., van Apeldoorn, A. A., Engelse, M. A., Zaldumbide, A., Bonner‐Weir, S., Rabelink, T. J., Hoeben, R. C., Clevers, H. C., et al. (2013) · Diabetes · doi:10.2337/db12-1001 · Cited by 151
Progress of Nanotechnology in Diabetic Retinopathy Treatment
Liu, Y., & Wu, N. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s294807 · Cited by 147
Satoh, T. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151018677 · Cited by 140
Structural determinants of dual incretin receptor agonism by tirzepatide
Sun, B., Willard, F. S., Feng, D., Alsina‐Fernandez, J., Chen, Q., Vieth, M., Ho, J. D., Showalter, A. D., Stutsman, C., Ding, L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116506119 · Cited by 136
β-cell dedifferentiation in diabetes is important, but what is it?
Weir, G. C., Aguayo‐Mazzucato, C., & Bonner‐Weir, S. (2013) · Islets · doi:10.4161/isl.27494 · Cited by 131
Progressing haemorrhagic stroke: categories, causes, mechanisms and managements
Chen, S., Zeng, L., & Hu, Z. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7291-1 · Cited by 128
Kimple, M. E., Keller, M. P., Rabaglia, M. R., Pasker, R. L., Neuman, J. C., Truchan, N. A., Brar, H. K., & Attie, A. (2013) · Diabetes · doi:10.2337/db12-0769 · Cited by 126
Mitochondria in Diabetic Kidney Disease
Ahmad, A. A., Draves, S. O., & Rosca, M. G. (2021) · Cells · doi:10.3390/cells10112945 · Cited by 126
Fontès, G., Zarrouki, B., Hagman, D. K., Latour, M. G., Semache, M., Roskens, V. A., Moore, P. C., Prentki, M., Rhodes, C. J., Jetton, T. L., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1850-5 · Cited by 121
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121
Energy balance and metabolic changes with sodium‐glucose co‐transporter 2 inhibition
Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12578 · Cited by 118
Metabolites Linking the Gut Microbiome with Risk for Type 2 Diabetes
Zhu, T., & Goodarzi, M. O. (2020) · Current Nutrition Reports · doi:10.1007/s13668-020-00307-3 · Cited by 118
Brown, E. E., Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13650 · Cited by 117
Paciaroni, M., & Acciarresi, M. (2019) · Stroke · doi:10.1161/strokeaha.119.023552 · Cited by 117
Malyar, N. M., Freisinger, E., Meyborg, M., Lüders, F., Gebauer, K., Reinecke, H., & Lawall, H. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.03.033 · Cited by 112
The Effect of Diet and Lifestyle on the Course of Diabetic Retinopathy—A Review of the Literature
Bryl, A., Mrugacz, M., Falkowski, M., & Zorena, K. (2022) · Nutrients · doi:10.3390/nu14061252 · Cited by 112
Nonproteinuric diabetic kidney disease
Yamanouchi, M., Furuichi, K., Hoshino, J., Ubara, Y., & Wada, T. (2020) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01881-0 · Cited by 108
Exertional Leg Pain in Patients With and Without Peripheral Arterial Disease
Wang, J. C., Criqui, M. H., Denenberg, J. O., McDermott, M. M., Golomb, B. A., & Fronek, A. (2005) · Circulation · doi:10.1161/circulationaha.105.548099 · Cited by 107
Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP
Thielen, L. A., & Shalev, A. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000391 · Cited by 103
Stanhope, K. L., Goran, M. I., Bosy‐Westphal, A., King, J. C., Schmidt, L. A., Schwarz, J., Stice, E. M., Sylvetsky, A. C., Turnbaugh, P. J., Bray, G. A., et al. (2018) · Obesity Reviews · doi:10.1111/obr.12699 · Cited by 100
Diabetic Kidney Disease: Diagnosis, Treatment, and Prevention.
McGrath, K. L., & Edi, R. (2019) · PubMed · Cited by 100
Yang, X., Li, Z., & Sun, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00711 · Cited by 95
Leg symptom categories and rates of mobility decline in peripheral arterial disease
McDermott, M. M., Ferrucci, L., Liu, K., Guralnik, J. M., Tian, L., Liao, Y., & Criqui, M. H. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02941.x · Cited by 90
Arunagiri, A., Haataja, L., Cunningham, C. N., Shrestha, N., Tsai, B., Qi, L., Liu, M., & Arvan, P. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13531 · Cited by 89
Mitochondrial dynamics and morphology in beta-cells
Stiles, L., & Shirihai, O. S. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.05.004 · Cited by 83
Diversity of pathophysiology in type 2 diabetes shown by islet pathology
Mizukami, H., & Kudoh, K. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13679 · Cited by 82
Role of Mitochondria in β-cell Function and Dysfunction
Maechler, P., Li, N., Casimir, M., Vetterli, L., Frigerio, F., & Brun, T. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_9 · Cited by 81
Roelofsen, H., Priebe, M., & Vonk, R. (2010) · Beneficial Microbes · doi:10.3920/bm2010.0028 · Cited by 80
Fedele, F., Mancone, M., Chilian, W. M., Severino, P., Canali, E., Logan, S. J., Marchis, M. L. D., Volterrani, M., Palmirotta, R., & Guadagni, F. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0387-4 · Cited by 79
Fu, J., Cui, Q., Yang, B., Hou, Y., Wang, H., Xu, Y., Wang, D., Zhang, Q., & Pi, J. (2016) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.12.016 · Cited by 66
Non-genetic mechanisms of diabetic nephropathy
Han, Q., Zhu, H., Chen, X., & Liu, Z. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0569-9 · Cited by 66
Naseri, K., Saadati, S., Ghaemi, F., Ashtary‐Larky, D., Asbaghi, O., Sadeghi, A., Afrisham, R., & de Courten, B. V. (2022) · European Journal of Nutrition · doi:10.1007/s00394-022-03012-9 · Cited by 66
Wittenbecher, C., Kuxhaus, O., Boeing, H., Stefan, N., & Schulze, M. B. (2019) · Diabetologia · doi:10.1007/s00125-019-04978-8 · Cited by 65
Fisher, V., Li, W. W., & Malabu, U. H. (2023) · Applied Psychology Health and Well-Being · doi:10.1111/aphw.12441 · Cited by 65
Naseri, K., Saadati, S., Ashtary‐Larky, D., Asbaghi, O., Ghaemi, F., Pashayee-Khamene, F., Yari, Z., & de Courten, B. V. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106399 · Cited by 63
Balasubaramaniam, V., & Pouwels, S. (2023) · Medicina · doi:10.3390/medicina59050985 · Cited by 62
Approaches to Peripheral Artery Disease in Diabetes: Are There Any Differences?
Achim, A., Stanek, A., Homorodean, C., Spînu, M., Onea, H., Lazăr, F.-L., Marc, M., Ruzsa, Z., & Olinic, D.-M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19169801 · Cited by 60
Carboneau, L., Allan, J. A., Townsend, S. E., Kimple, M. E., BREYER, R. M., & GANNON, M. A. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.002 · Cited by 54
Boland, B. B., Brown, C. L., Boland, M. L., Cann, J. A., Sulikowski, M., Hansen, G., Grønlund, R. V., King, W., Rondinone, C. M., Trevaskis, J. L., et al. (2018) · Diabetes · doi:10.2337/db18-0304 · Cited by 54
Qureshi, A. I., Huang, W., Lobanova, I., Chandrasekaran, P. N., Hanley, D. F., Hsu, C. Y., Martin, R. H., Steiner, T., Suárez, J. I., Yamamoto, H., et al. (2021) · Stroke · doi:10.1161/strokeaha.121.034928 · Cited by 54
Moin, A. S. M., Dhawan, S., Cory, M., Butler, P. C., Rizza, R. A., & Butler, A. E. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2496 · Cited by 53
Persistent Hyperglycemia Is Associated With Increased Mortality After Intracerebral Hemorrhage
Wu, T. Y., Jukka Putaala, A., Sharma, G. J., Strbian, D., Tatlisumak, T., Davis, S. M., & Meretoja, A. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005760 · Cited by 53
Hyperbaric oxygen therapy for chronic diabetic foot ulcers: An overview of systematic reviews
Li, W., Fu, C., Lei, X., Baozhong, Y., Guobin, L., & Fan, W. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108862 · Cited by 52
High fat programming of beta cell compensation, exhaustion, death and dysfunction
Cerf, M. E. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12137 · Cited by 48
Li, Y., Storch, E. A., Ferguson, S., Li, L., Buys, N., & Sun, J. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109965 · Cited by 47 · cited 1×
“The results of a meta-analysis indicate a significant reduction in HbA1c, fasting blood glucose, and diastolic blood pressure (DBP) in patients with diabetes on CBT [132].”
Bahadar, G. A., & Shah, Z. A. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210223145112 · Cited by 47
Contemporary evaluation and management of lower extremity peripheral artery disease
Foley, T. R., Armstrong, E. J., & Waldo, S. W. (2016) · Heart · doi:10.1136/heartjnl-2015-309076 · Cited by 45
Fighting Diabetes Mellitus: Pharmacological and Non-pharmacological Approaches
Wang, X., Kang, J., Liu, Q., Tong, T., & Quan, H. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200728144200 · Cited by 45
Insulin action on the liver in vivo
Cherrington, A. D., Moore, M. C., Sindelar, D. K., & Edgerton, D. S. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351171 · Cited by 43
Gargano, J. W., Wehner, S., & Reeves, M. J. (2010) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2010.02.022 · Cited by 43
Cellular mechanism of insulin resistance in skeletal muscle.
Petersen, K. F., & Shulman, G. I. (2002) · Europe PMC (PubMed Central) · Cited by 41
Validation of Insulin Sensitivity and Secretion Indices Derived from the Liquid Meal Tolerance Test
Maki, K. C., Kelley, K., Lawless, A. L., Hubacher, R., Schild, A. L., Dicklin, M. R., & Rains, T. M. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0240 · Cited by 40
Advances in the genetics of nonalcoholic fatty liver disease
Ajmera, V. H., & Loomba, R. S. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000927 · Cited by 40
Present and future directions in diabetic kidney disease
Limonte, C. P., Kretzler, M., Pennathur, S., Pop‐Busui, R., & de Boer, I. H. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108357 · Cited by 39
Pearson, T., Wattis, J. A. D., King, J. R., MacDonald, I. A., & Mazzatti, D. J. (2016) · Bulletin of Mathematical Biology · doi:10.1007/s11538-016-0181-1 · Cited by 37 · cited 1×
“IR can be a result of decreased insulin secretion, insulin antagonists in the plasma, and diminished insulin response in target tissues [52].”
Sigfrid, L., Cunningham, J. M., Beeharry, N., Borg, L. A. H., Hernandez, A. L. R., Carlsson, C., Bone, A. J., & Green, I. C. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0533-4 · Cited by 37
Type 2 diabetes and the progression of visualized atherosclerosis to clinical cardiovascular events
Saely, C. H., Rein, P., Vonbank, A., Huber, K., & Drexel, H. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.042 · Cited by 34
Ten-year duration of type 2 diabetes as prognostic factor for remission after sleeve gastrectomy
Casella, G., Abbatini, F., Calì, B., Capoccia, D., Leonetti, F., & Basso, N. (2011) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2011.08.014 · Cited by 33
The Importance of REST for Development and Function of Beta Cells
Martin, D. J., & Grapin‐Botton, A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00012 · Cited by 31
Management of diabetic kidney disease: where do we stand?: A narrative review
Sindhu, D., Sharma, G. S., & Kumbala, D. R. (2023) · Medicine · doi:10.1097/md.0000000000033366 · Cited by 31
Singhal, S., Patil, V. M., Verma, S. K., & Masand, N. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107277 · Cited by 31
Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity
Sardar, M. B., Nadeem, Z. A., & Babar, M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102489 · Cited by 30
Aslamy, A., Wood, A. C., Jensen, E. T., Bertoni, A. G., Sheridan, P. A., Wong, K. E., Ramesh, G., Rotter, J. I., Chen, Y.-D. I., & Goodarzi, M. O. (2023) · Diabetes · doi:10.2337/db23-0401 · Cited by 26
Yuan, Y., Chen, C., Liu, Q., Luo, Y., Yang, Z., Lin, Y., Sun, L., & Fan, G. (2024) · Food & Function · doi:10.1039/d4fo00337c · Cited by 25
Kermansaravi, M., Chiappetta, S., Kassir, R., Bosco, A., Giudicelli, X., Laïnas, P., & Safieddine, M. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07564-z · Cited by 24
Rodrigo‐Carbó, C., Madinaveitia‐Nisarre, L., Pérez‐Calahorra, S., Gracia‐Rubio, I., Cebollada, A., Galindo‐Lalana, C., Mateo‐Gállego, R., & Lamíquiz-Moneo, I. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16013 · Cited by 21
When Less Is Better: ER Stress and Beta Cell Proliferation
Yong, J., Itkin‐Ansari, P., & Kaufman, R. J. (2016) · Developmental Cell · doi:10.1016/j.devcel.2015.12.030 · Cited by 19
Gateva, A., Assyov, Y. S., Velikova, T. V., & Kamenov, Z. A. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.11.056 · Cited by 19
Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. Reply.
Frías, J. P., Landó, L. F., & Brown, K. E. (2022) · PubMed · doi:10.1056/nejmc2114590 · Cited by 16
Clinical use of GLP-1 agonists and DPP4 inhibitors
Tuch, B. E. (2015) · Pancreatology · doi:10.1016/j.pan.2015.05.465 · Cited by 15
Impact of higher BMI on cardiometabolic risk: does height matter?
Stefan, N., Schiborn, C., Machann, J., Birkenfeld, A. L., & Schulze, M. B. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00164-5 · Cited by 15
Baitule, S., Patel, A., Murthy, N., et al. (2021) · Medicina · doi:10.3390/medicina57101134 · Cited by 13
Sadeghi, S., Hosseinpanah, F., Khalaj, A., Ebadinejad, A., Mahdavi, M., Valizadeh, M., & Barzin, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15974 · Cited by 11
Samsudeen, H., Varaj, S. P. D., & Kandasamy, K. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998275876240125064716 · Cited by 8
Azócar-Gallardo, J., Ojeda-Aravena, A., Martín, E. B.-S., Herrera-Valenzuela, T., Tuesta, M., González-Rojas, L., Rico, B. C., & García‐García, J. M. (2024) · Biomolecules · doi:10.3390/biom14111470 · Cited by 8
Metadata
- Authors
- Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2025-01-27
- Volume
- 26
- Issue
- 3
- Pages
- 1094
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4406846918
- Cited by
- 328
- References
- 199
- FWCI
- 195.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.